Skip to main content
OpenTrials
Completed

NCT Number: NCT03319264

Sarcopenia in Axial and Peripheral Spondyloarthropathies

Spondylarthropathies (SpA) are among the most common chronic inflammatory rheumatisms in adults, responsible for a muscular loss or sarcopenia which can be very disabling, not much documented in the literature, and not yet studied in France. In addition, sarcopenia is associated with decreased physical activity and increased risk of falls and fractures. A better characterization of the determinants of this muscular loss will allow to better detect and take care of it.

The aim is to conduct the first French study on the prevalence and severity of sarcopenia in patients with spondyloarthropathies and to study the variables that may be associated with it. Finally, we propose to evaluate obesity related to sarcopenia in these patients and compare them to cases matched for age and sex (from OFELY / STRAMBO cohorts, Lyon, FRANCE).

This is a prospective interventional and monocentric study with minimal risks and constraints: patients will be included for one day for an evaluation of their sarcopenia by measuring their muscle strength, physical performance and body composition and recording of their socio-demographic and disease characteristics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Spondylarthropathy Arthritis Atrophy Bone Diseases Joint Diseases Muscular Atrophy Musculoskeletal Diseases Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Sarcopenia Signs and Symptoms Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de Rhumatologie - Hôpital Edouard Herriot

Lyon, 69003, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women, 18 to 80 years old
  • Hospitalized or attending the rheumatology department for spondyloarthopathy.

Exclusion criteria

  • no signed consent
  • Immobilization for a period of more than 15 days during the last 3 months
  • pregnant or breastfeeding woman
  • Not affiliated to the national healthcare insurance
  • difficulty in understanding French
  • psychiatric disorder

Treatment and study plan

Dynamometry exam

Other

Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength

walking test

Other

A 4 metres walking test will be performed to assess patient's walking speed

DXA measurement

Radiation

DXA measurement will be performed to assess patient's body composition

SARQOL questionnaire

Other

Patient's quality of life will be assessed thanks to the SARQOL questionnaire

Life habits Questionnaire

Behavioral

Life habits Questionnaire

Primary outcomes

  1. Muscular strength

    Time frame: At day 1

    Muscular strength is the first outcome to evaluate sarcopenia

  2. Walking speed

    Time frame: At day 1

    Walking speed is a physical performance outcome, that is the second outcome to evaluate sarcopenia

  3. Muscular mass

    Time frame: Up to 4 month after inclusion

    Muscular mass is the third outcome to evaluate sarcopenia and will be assessed using DXA

Secondary outcomes

  1. Alcohol consumption

    Time frame: At day 1

  2. Tobacco consumption

    Time frame: At day 1

  3. Time of sport practice per month

    Time frame: At day 1

    Number of hours of sport practice per month is the first outcome to evaluate patient's global physical activity.

  4. Physical activity rate in work

    Time frame: At day 1

    Physical activity rate in work can be light, medium, high or not applicable if the patient does not work ; it is the second outcome to evaluate patient's physical global activity.

  5. Average walking time in a week

    Time frame: At day 1

    Average walking time in a week is the third outcome to evaluate patient's physical global activity.

  6. Score at the SARQOL questionnaire

    Time frame: At day 1

    Quality of life will be assessed thanks to the SARQOL questionnaire (score between 0 and 100)

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: SASPAR

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Oct 24, 2017
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.